News & Updates

Show Multimedia Only

Three-month DAPT post MI may suffice

23 Sep 2025 by

Although guidelines recommend 12 months of dual antiplatelet therapy (DAPT) following a heart attack, results from the DUAL-ACS* trial appear to show otherwise.

Three-month DAPT post MI may suffice

23 Sep 2025

Rifasutenizol tackles H. pylori infection

23 Sep 2025

Rifasutenizol demonstrates efficacy in the treatment of Helicobacter pylori infection, according to the results of the phase III EVEREST-HP trial.

Rifasutenizol tackles H. pylori infection

23 Sep 2025

Olezarsen lowers triglycerides in patients with moderate HTG, high CV risk

23 Sep 2025 by

Treatment with olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with moderate hypertriglyceridaemia (HTG) and elevated cardiovascular (CV) risk compared with placebo, according to the Essence-TIMI 73b trial presented at ESC 2025.

Olezarsen lowers triglycerides in patients with moderate HTG, high CV risk

23 Sep 2025

Add-on baxdrostat shows promise for hard-to-control BP

22 Sep 2025 by

In the phase III BaxHTN trial, the highly selective and potent aldosterone synthase inhibitor baxdrostat efficiently controls blood pressure (BP) when added to background antihypertensive therapy for the treatment of uncontrolled or treatment-resistant hypertension (HTN).

Add-on baxdrostat shows promise for hard-to-control BP

22 Sep 2025

Semaglutide works well for Asians with obesity

22 Sep 2025

Once-weekly treatment with semaglutide is safe and induces weight loss in Asians with obesity, according to the phase III STEP 11 trial.

Semaglutide works well for Asians with obesity

22 Sep 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-August-2025

22 Sep 2025

New drug applications approved by US FDA as of 1-15 August 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-August-2025

22 Sep 2025

GLP-1 RAs work well for managing T2D, obesity in children

21 Sep 2025 by

Children and teens with type 2 diabetes (T2D) or obesity benefit from glucagon-like peptide-1 receptor agonists (GLP-1RAs), which help improve blood sugar and weight, according to a meta-analysis.

GLP-1 RAs work well for managing T2D, obesity in children

21 Sep 2025

Which antibiotic regimen is best for paediatric appendicitis?

21 Sep 2025 by

The use of antibiotics to treat paediatric appendicitis should target Escherichia coli and anaerobes, suggests a study. Two other bacteria are also present in about a fourth of the cultures, namely viridans group streptococci (VGS) and pseudomonas.

Which antibiotic regimen is best for paediatric appendicitis?

21 Sep 2025

Dotinurad bests febuxostat for Chinese patients with gout

21 Sep 2025

In the treatment of Chinese patients with gout, the use of dotinurad results in a higher response rate compared with febuxostat, according to a phase III study.

Dotinurad bests febuxostat for Chinese patients with gout

21 Sep 2025

No link between IBD treatment and breast cancer

20 Sep 2025

Medications used to treat inflammatory bowel disease (IBD) do not contribute to an increase in the risk of breast cancer, according to a retrospective study.

No link between IBD treatment and breast cancer

20 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Three-month DAPT post MI may suffice

Three-month DAPT post MI may suffice

Rifasutenizol tackles H. pylori infection

Rifasutenizol tackles H. pylori infection

Olezarsen lowers triglycerides in patients with moderate HTG, high CV risk

Olezarsen lowers triglycerides in patients with moderate HTG, high CV risk

Add-on baxdrostat shows promise for hard-to-control BP

Add-on baxdrostat shows promise for hard-to-control BP

Semaglutide works well for Asians with obesity

Semaglutide works well for Asians with obesity

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-August-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-August-2025

GLP-1 RAs work well for managing T2D, obesity in children

GLP-1 RAs work well for managing T2D, obesity in children

Which antibiotic regimen is best for paediatric appendicitis?

Which antibiotic regimen is best for paediatric appendicitis?

Dotinurad bests febuxostat for Chinese patients with gout

Dotinurad bests febuxostat for Chinese patients with gout

No link between IBD treatment and breast cancer

No link between IBD treatment and breast cancer